Pretargeting of carcinoembryonic antigen - Expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells

Clinical Cancer Research

Volumn 11, Issue 19 II, 2005, Pages

  Rossi, Edmund A ^a   Chang, Chien Hsing ^a,b   Losman, Michelle J ^a   Sharkey, Robert M ^c   Karacay, Habibe ^c   McBride, William ^b   Cardillo, Thomas M ^b   Hansen, Hans J ^b   Qu, Zhengxing ^b   Horak, Ivan D ^b   Goldenberg, David M ^a,b,c  

^a IBC Pharmaceuticals Inc   (United States)

^b IMMUNOMEDICS INC   (United States)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; HAPTEN; HBS14 PROTEIN; HISTAMINE SUCCINYLGLYCINE; HYBRID PROTEIN; IMP 241; INDIUM 111; IODINE 125; IODINE 131; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN EXPRESSION; BINDING SITE; CONFERENCE PAPER; DRUG TARGETING; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOLECULAR WEIGHT; MOUSE; MYELOMA CELL; NONHUMAN; NUDE MOUSE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, BISPECIFIC; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; CHROMATOGRAPHY; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLONING, MOLECULAR; DIMERIZATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENETIC VECTORS; HAPTENS; INDIUM RADIOISOTOPES; ISOELECTRIC FOCUSING; MICE; MICE, NUDE; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; OPEN READING FRAMES; PEPTIDES; PROTEIN BINDING; RADIOIMMUNODETECTION; RADIOISOTOPES; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TISSUE DISTRIBUTION; TRANSFECTION;

EID: 26444530095     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1004-0020     Document Type: Conference Paper

References (25)

1. Goldenberg DM. Targeted therapy of cancer with radio-labeled antibodies. J Nucl Med 2002;43:693-713.
2. Chang C-H, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther 2002;1: 553-63.
3. Le Doussal J-M, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radio-labeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: Enhanced divalent hapten affinity for cell bound antibody conjugates. J Nucl Med 1989;30:1358-66.
4. 90Y radioimmunotherapy in a mouse xenograft model. J Immunother 1994;16:158.
5. Vuillez JP, Kraeber-Bodere F, Moro D, et al. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 di-DTPA hapten: results of a phase I/II trial. Clin Cancer Res 1999;10: 3259-67s.
6. Kraeber-Bodere F, Bardet S, Hoefnagel CA, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res 1999;10:3190-8s.
7. 131I-labeled bivalent DTPA hapten in patients with CEA-expressing tumor [abstract]. J Nucl Med 2001;42:123p.
8. 131I-labeled hapten in pretargeted radioimmunotherapy patients [abstract]. J Nucl Med 2002;43:159p.
9. 188Re-labeled peptide. Bioconjug Chem 2000;11:842-54.
10. Morel A, Darmon M, Delaage M. Recognition of imidazole and histamine derivatives by monoclonal antibodies. Mol Immunol 1990;27:995-1000.
11. Sharkey RM, McBride WJ, Karacay H, et al. A universal pre-targeting system for cancer detection and therapy using bispecific antibody. Cancer Res 2003;63: 354-63.
12. Sharkey RM, Karacay H, McBride WJ, Chang K, Hansen HJ, Goldenberg DM. Therapeutic results using a novel bispecific antibody pretargeting system for the delivery of Y-90 [abstract 559]. J Nucl Med 2002; 43:154P.
13. Rossi EA, Sharkey RM, McBride W, et al. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res 2003;9:3886-963.
14. Karacay H, Sharkey RM, McBride WJ, et al. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen. Bioconjug Chem 2002;13: 1054-70.
15. Gillies SD, Lo KM, Wesolowski J. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods 1989;125: 191-202.
16. Losman MJ, Hansen HJ, Dworak H, et al. Generation of a high-producing clone of a human anti B cell lymphoma monoclonal antibody (hLL2). Cancer 1997;80:2660-6.
17. Losman MJ, Novick KE, Goldenberg DM, Monestier M. Mimicry of a carcinoembryonic antigen epitope by a rat monoclonal anti-idiotype antibody. Int J Cancer 1994;56:580-4.
18. Goldenberg DM, Hansen HJ. Carcinoembryonic antigen present in human colonic neoplasms serially propagated in hamsters. Science 1972;175:1117-8.
19. Weadock KS, Sharkey RM, Varga DC, Goldenberg DM. Evaluation of a remote radioiodination system for radioimmunotherapy. J Nucl Med 1990;31:508-11.
20. Sharkey RM, Karacay H, Richel H, et al. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res 2003;9:3897-913s.
21. Kranenborg MHGC, Boerman OC, Oosterwijk-Wakka JC, deWeijert MCA, Corstens FHM, Oosterwijk E. Development and characterization of anti-renal cell carcinoma x anti-DTPA bispecific monoclonal antibody for two-phase targeting of renal cell carcinoma. Cancer Res 1995;55:1529-37s.
22. Hudson PJ. Recombinant antibody constructs in cancer therapy. Curr Opin Immunol 1999;11:548-57.
23. Hudson PJ, Kortt AA. High avidity scFv multimers; diabodies and triabodies. J Immunol Methods 1999; 231:177-89.
24. Wu AM, Tan GJ, Sherman MA, et al. Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng 2001;14:1025-33.
25. Kortt AA, Malby RL, Caldwell JB, et al. Recombinant anti-sialidase single-chain variable fragment antibody characterization, formation of dimerand higher-molecular-mass multimers and the solution of the crystal stucture of the single-chain variable fragment/sialidase complex. Eur J Biochem 1994;221:151-7.